Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Ivosidenib Patent Expiration

Ivosidenib is Used for treating AML, cholangiocarcinoma, and myelodysplastic syndromes with IDH1 mutations. It was first introduced by Servier Pharmaceuticals Llc in its drug Tibsovo on Jul 20, 2018.


Ivosidenib Patents

Given below is the list of patents protecting Ivosidenib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tibsovo US10449184 Pharmaceutical compositions of therapeutically active compounds Mar 13, 2035 Servier
Tibsovo US10610125 Methods and compositions for cell-proliferation-related disorders Jun 21, 2030 Servier
Tibsovo US10653710 Combination therapy for treating malignancies Oct 18, 2036 Servier
Tibsovo US10717764 Therapeutically active compounds and their methods of use Jan 18, 2033 Servier
Tibsovo US10799490 Pharmaceutical compositions of therapeutically active compounds Mar 13, 2035 Servier
Tibsovo US10980788 Therapy for treating malignancies Jun 07, 2039 Servier
Tibsovo US11667673 Therapeutically active compounds and their methods of use Jan 18, 2033 Servier
Tibsovo US9474779 Therapeutically active compositions and their methods of use Aug 19, 2033 Servier
Tibsovo US9850277 Therapeutically active compositions and their methods of use Jan 18, 2033 Servier
Tibsovo US9968595 Pharmaceutical compositions of therapeutically active compounds Mar 13, 2035 Servier


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ivosidenib's patents.

Given below is the list recent legal activities going on the following patents of Ivosidenib.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 25 Apr, 2024 US9474779
Payment of Maintenance Fee, 4th Year, Large Entity 22 Jan, 2024 US10717764
Payment of Maintenance Fee, 4th Year, Large Entity 20 Nov, 2023 US10653710
Patent Issue Date Used in PTA Calculation 06 Jun, 2023 US11667673
Mail Patent eGrant Notification 06 Jun, 2023 US11667673
Email Notification 06 Jun, 2023 US11667673
Recordation of Patent eGrant 06 Jun, 2023 US11667673
Patent eGrant Notification 06 Jun, 2023 US11667673
Electronic Review 06 Jun, 2023 US11667673
Recordation of Patent Grant Mailed 06 Jun, 2023 US11667673



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳